INmune Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INMB research report →
Companywww.inmunebio.com
INmune Bio, Inc. , a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
- CEO
- David J. Moss
- IPO
- 2019
- Employees
- 13
- HQ
- Boca Raton, FL, US
Price Chart
Valuation
- Market Cap
- $37.49M
- P/E
- -0.90
- P/S
- 0.00
- P/B
- 1.91
- EV/EBITDA
- -0.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -170.86%
- ROIC
- -204.84%
Growth & Income
- Revenue
- $50.00K · 257.14%
- Net Income
- $-45,933,000 · -9.15%
- EPS
- $-1.86 · 11.85%
- Op Income
- $-30,869,000
- FCF YoY
- 29.19%
Performance & Tape
- 52W High
- $11.64
- 52W Low
- $1.09
- 50D MA
- $1.34
- 200D MA
- $1.69
- Beta
- 1.05
- Avg Volume
- 469.60K
Get TickerSpark's AI analysis on INMB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 1, 25 | Moss David J | other | 750,000 |
| Dec 1, 25 | Lowdell Mark William | other | 600,000 |
| Dec 1, 25 | Ellspermann Cory Randall | other | 300,000 |
| Dec 1, 25 | Schroeder Timothy j | other | 150,000 |
| Dec 1, 25 | Juda Scott | other | 150,000 |
| Dec 1, 25 | Ganjei James Kelly | other | 150,000 |
| Dec 1, 25 | ALLEN MARCIA | other | 150,000 |
| Nov 18, 25 | Schroeder Timothy j | other | 108,000 |
| Nov 18, 25 | Schroeder Timothy j | other | 35,000 |
| Nov 18, 25 | Schroeder Timothy j | other | 32,500 |
Our INMB Coverage
We haven't published any research on INMB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INMB Report →